Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAV2sFLT 01 - Applied Genetic Technologies

Drug Profile

AAV2sFLT 01 - Applied Genetic Technologies

Alternative Names: AAV2-sFLT01; age-related macular degeneration gene therapy - Applied Genetic Technologies; anti vascular endothelial growth factor (VEGF) gene therapy - Applied Genetic Technologies; GZ-402663; sFLT-01

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation; Genzyme Corporation
  • Developer Applied Genetic Technologies Corporation; Genzyme Corporation; JDRF
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 01 Jul 2018 Phase I development in Age-related macular degeneration is ongoing in USA (Intravitreous) (NCT01024998)
  • 01 Jul 2018 Genzyme completes a phase I trial in Age-related macular degeneration in USA (Intravitreous) (NCT01024998)
  • 16 Jul 2013 Genzyme enters cross-license agreement for use of Asklepios BioPharmaceutical's Duplex gene therapy vector technology for Genzyme's internal product development research (including AAV2sFLT-01 for age-related macular degeneration) and external sublicensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top